• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore, Jan. 17 Biocon Ltd posted a standalone profit after tax of Rs 45.58 crore for the third quarter ending December 31, 2007, down about 4 per cent (Rs 47.51 crore) from the same period the previous year. This, however, excludes the one-time exceptional pre-tax gain the company made during the quarter after it sold its enzymes business; including that gain, the net profit was just over Rs 284 crore. Biocon sold its enzymes business to Novozymes during the previous quarter for $ 115 million (around Rs 460 crore). This also reflected as a Q3 pre-tax profit of Rs 330 crore on a consolidated basis, the company said.

Net sales of Rs 194.19 crore for the October-December 2007 quarter was 9.2 per cent lower year on year. The enzymes divestment again perked up the total income to Rs 219.62 crore.

Consolidated nine-month revenues touched Rs 811 crore, and excluding the enzymes business, grew 21 per cent year on year. It showed an EBITDA of Rs 240 crore, up 20 per cent; and profit after tax of Rs 160 crore, up 15 per cent.

More Stories on : Bio-tech & Genetics

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Focus on product mix boosts Rallis Q3 net 61%

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line